Maynard Ryan D's Form 4 filing
Iovance Biotherapeutics, Inc. (IOVA) · filed Nov 14, 2024
- Accession no.
- 0001104659-24-119195
- Filed
- Nov 14, 2024
- Trade date
- Nov 12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $503.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maynard Ryan DCIK 0001363984 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Common Stock | MOption exerciseAcquired | +50,000 | $7.45 | +$372,500 | 57,500 | Direct | |
| Nov 12, 2024 | Common Stock | SSaleDisposed | −50,000 | $10.06F3 | −$503,000 | 7,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $10.05 and $10.105.
Referenced by the price of 1 transaction in Table I.